This is a securities class action lawsuit against China Shenghuo Pharmaceutical Holdings.
China Shenghuo develops products derived from herbs to treat a myriad of health conditions, ranging from cardiovascular disease to the common cold.
On August 20, 2008, China Shenghuo issued a press release stating that its financial statements for the periods ended June 30, September 30, and December 30, 2007, and the fiscal quarter ended March 31, 2008, contained accounting errors and should not be relied on until China Shenghuo issued a financial restatement for those quarters. This disclosure allegedly prompted China Shenghuo common stock to lose 19 percent of its value on that day, closing at $1.89 per share. The AMEX halted the sale of the stock at closing on August 20, 2008, and trading on China Shenghuo common stock currently remains halted.
Name (Stock Symbol)
China Shenghuo Pharmaceutical Holdings, Inc. (KUN)
China Shenghuo Pharmaceutical Holdings, Inc. and its subsidiaries engage in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement, and cosmetic products China.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.